Sara Mogedano Cruz | Oncology | Young Scientist Award

Published on by Global Scholar Awards

Mrs. Sara Mogedano Cruz | Oncology | Young Scientist Award

Universidad Europea de Madrid | Spain

Sara Mogedano-Cruz is a developing scholar in the field of biomedical and clinical sciences, affiliated with the Universidad Europea de Madrid in Villaviciosa de Odón, Spain, where she focuses on anatomical variability, anthropometric modeling, and evidence-based approaches to improving procedural safety. Her research emphasizes the integration of quantitative anatomical assessment into clinical workflows to enhance precision, reduce risk, and support safer invasive procedures. She has contributed to interdisciplinary studies that bridge anatomy, physiotherapy, clinical biomechanics, and medical engineering, strengthening the translation of scientific evidence into patient-centered practice. Her notable work includes the publication Predicting Median Nerve Depth from Anthropometric Features: A Tool for Safer Invasive Procedures, which examines how anthropometric predictors can guide clinicians in estimating nerve depth more accurately. Additionally, she co-authored the case report Percutaneous Peripheral Nerve Stimulation in Chemotherapy-Induced Neuropathy, reflecting her engagement with clinically meaningful interventions and her involvement in research that intersects neuromuscular assessment and oncology-related neuropathy. With five indexed documents and collaborations with national and international researchers, her scholarship is gaining visibility, supported by a growing citation record that underscores the relevance of her work to emerging clinical methodologies. Through her commitment to methodological rigor and multidisciplinary inquiry, she aims to advance innovations that connect anatomical science, clinical decision-making, and technological development for improved patient outcomes and broader societal benefit. Sara Mogedano-Cruz’s academic influence and research productivity are reflected in her metrics: 18 citations, 5 documents, and an h-index of 1.

Profiles: Scopus | ORCID

Featured Publication

1. Mogedano-Cruz, S., González-de-la-Flor, Á., Rodríguez-Anadón, C., Bohn, L., Villafañe, J., & Romero-Morales, C. (2025). Predicting median nerve depth from anthropometric features: A tool for safer invasive procedures. PLoS ONE, 20(8), e0330383. (Cited by: 1).

Probal Banerjee | Cancer Biology | Best Researcher Award

Published on by Global Scholar Awards

Prof. Probal Banerjee | Cancer Biology | Best Researcher Award

Professor| University of New York | United States

Dr. Probal Banerjee is a distinguished Professor of Chemistry and Coordinator of the Center for Developmental Neuroscience at The College of Staten Island, City University of New York, renowned for his pioneering contributions at the intersection of chemistry, neuroscience, and molecular pharmacology. Holding a Ph.D. in Bioorganic Chemistry from the Indian Institute of Science, Bangalore, and postdoctoral training at the University of Notre Dame and the University of Chicago, he has produced over 100 peer-reviewed publications that have advanced understanding of serotonergic signaling in brain development and innovative therapeutic strategies in cancer biology. His groundbreaking research on the 5-HT1A receptor’s role in neonatal hippocampal neurogenesis and on curcumin-based multi-target cancer therapies has redefined approaches to neurodevelopmental and oncological disorders, emphasizing immune modulation and translational impact. Dr. Banerjee’s recent studies on immune-friendly prodrugs and synergistic natural compounds reflect his commitment to safe, mechanism-driven, and sustainable therapeutic innovation. A frequent invited speaker at global scientific forums including Columbia University, NASA Ames, and the Indian Institute of Science, he collaborates internationally to bridge fundamental discovery with clinical relevance. Recognized with multiple honors such as the Brain Research Foundation Award and two Dolphin Awards for academic excellence and teaching, Dr. Banerjee continues to mentor emerging scientists and shape global biomedical research through his visionary work integrating molecular neuroscience, immunology, and drug development to enhance human health worldwide

Profiles: Scopus | ORCID

Featured Publications

Salutary effects of transdermal curcumin on multiple indices of health span in rodent models of normal aging and hypertension. Geroscience. 1 citation (2025).

Targeting sickle cell pathobiology and pain with novel transdermal curcumin. PNAS Nexus. 2 citations (2025).

Corrigendum: Dietary polyphenols, resveratrol and pterostilbene exhibit antitumor activity on an HPV E6-positive cervical cancer model: an in vitro and in vivo analysis. Frontiers in Oncology. 2 citations (2019).

Biocompatible anisole-nonlinear PEG core–shell nanogels for high loading capacity, excellent stability, and controlled release of curcumin. Gels. 8 citations (2023).

Why don’t the mutant cells that evade DNA repair cause cancer more frequently? Importance of the innate immune system in the tumor microenvironment. International Journal of Molecular Sciences. 4 citations (2023).

The G protein-coupled serotonin 1A receptor augments protein kinase Cε-mediated neurogenesis in neonatal mouse hippocampus—PKCε-mediated signaling in the early hippocampus. International Journal of Molecular Sciences. 2 citations (2022).

Dr. Probal Banerjee’s research bridges chemistry, neuroscience, and immunology to pioneer multi-target therapeutic strategies that combat cancer and neurodevelopmental disorders. His innovative work on curcumin-based immune therapies and serotonergic signaling mechanisms has advanced translational medicine, inspiring new, safer, and globally accessible approaches to human health and disease management.

William Skelton | Medical Oncology | Best Researcher Award

Published on by Global Scholar Awards

Dr. William Skelton | Medical Oncology | Best Researcher Award

Assistant Professor of Medicine at University of Virginia Comprehensive Cancer Center, United States

Dr. William Paul Skelton IV is an Assistant Professor of Medicine at the University of Virginia School of Medicine, specializing in Hematology and Oncology. With extensive training from prestigious institutions like Moffitt Cancer Center and the University of Florida, Dr. Skelton is a dedicated clinician and researcher in Genitourinary Oncology. His career is marked by numerous awards, including recognition for excellence in patient care and teaching. Dr. Skelton is committed to advancing cancer treatment through research and has a notable record of impactful publications and presentations in the field. His professional contributions extend to mentoring and serving on various academic committees.

Publication Profile

Education

Dr. William Paul Skelton IV completed his Hematology/Oncology Fellowship at Moffitt Cancer Center, University of South Florida, followed by a Chief Medical Residency at the University of Florida. He earned his Internal Medicine Residency from the same institution and graduated with honors in research from the University of Florida College of Medicine. Dr. Skelton holds a Magna Cum Laude degree in Chemistry from Duke University and a high school diploma with exceptional achievements from King International Baccalaureate High School.

Experience

Dr. Skelton’s professional journey includes his current role as an Assistant Professor of Medicine at the University of Virginia School of Medicine. Previously, he served as a Hematology/Oncology Fellow at Moffitt Cancer Center and as a Chief Medical Resident during his Internal Medicine Residency at the University of Florida. His clinical expertise encompasses Genitourinary Oncology, and he has contributed significantly to medical education through precepting and mentoring medical students, residents, and fellows.

Awards and Honors

Dr. Skelton has received several prestigious awards, including the Moffitt Cancer Center SPOTTED in FellowSHIP patient care Recognition Award in both 2020 and 2021. He was honored with the Florida ACP Chief Resident Award and the UF Senior Resident Medical Student Teaching Award. Additional accolades include the Craig S. Kitchens Outstanding Senior Medicine Resident Award and selection into the Alpha Omega Alpha Honor Society. His academic honors also include Phi Beta Kappa and the Merck Index Award.

Research Focus

Dr. Skelton’s research primarily focuses on Genitourinary Oncology, particularly the therapeutic advancements and molecular mechanisms underlying renal and bladder cancers. His work includes investigating predictive tools for advanced renal cancer and exploring the impact of systemic therapies on cancer progression. Dr. Skelton’s research is aimed at improving patient outcomes through innovative treatment strategies and clinical trials.

Publications Top Notes

  • Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
    • Authors: Skelton, W.P., Masur, J., Thomas, J., Jain, R.K., Sonpavde, G.P.
    • Journal: Clinical Genitourinary Cancer
    • Year: 2024
    • Citations: 0 💊💉🩺
  • Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus
    • Authors: Ali, S., Fortune, K., Masur, J., Dreicer, R., Skelton, W.P.
    • Journal: Clinical Genitourinary Cancer
    • Year: 2024
    • Citations: 0 🩸👨‍⚕️🧬
  • Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer
    • Authors: Altshuler, E., Franke, A.J., Skelton, W.P., Dai, Y., George, T.J.
    • Journal: Clinical Colorectal Cancer
    • Year: 2023
    • Citations: 2 🧬🔬
  • Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma
    • Authors: Zhang, Y., Kumar, P., Adashek, J.J., Manley, B.J., Spiess, P.E.
    • Journal: Cells
    • Year: 2022
    • Citations: 6 🧫🔬💊
  • FGFR2/3 Genomic Alterations and Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
    • Authors: Adib, E., El-Zarif, T., Jain, R.K., Choueiri, T.K., Sonpavde, G.P.
    • Journal: BJUI Compass
    • Year: 2022
    • Citations: 6 🧬💉🧪
  • Clinical Cases Debate: Neoadjuvant Versus Adjuvant Immunotherapy in Localized Renal Cell Carcinoma (RCC)
    • Authors: Skelton, W.P., Dahmen, A., Chatwal, M., Chahoud, J., Spiess, P.E.
    • Book Chapter: Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers
    • Year: 2022
    • Citations: 0 📖🦠💉
  • Optimal Pathological Response After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Results from a Global, Multicentre Collaboration
    • Authors: Ravi, P., Pond, G.R., Diamantopoulos, L.N., Grivas, P., Sonpavde, G.P.
    • Journal: BJU International
    • Year: 2021
    • Citations: 13 🧬🌍
  • Systematic Analysis of Extracting Data on Advance Directives from Patient Electronic Health Records (EHR) in Terminal Oncology Patients
    • Authors: Starr, J.S., Skelton, W.P., Rahmanian, K.P., George, T.J., Moseley, R.E.
    • Journal: Journal of Palliative Care
    • Year: 2021
    • Citations: 0 📊🩺📋
  • A Comprehensive Review of Randomized Clinical Trials Shaping the Landscape of Rectal Cancer Therapy
    • Authors: Franke, A.J., Skelton, W.P., George, T.J., Iqbal, A.
    • Journal: Clinical Colorectal Cancer
    • Year: 2021
    • Citations: 4 🧪📊
  • Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?
    • Authors: Adashek, J.J., Zhang, Y., Skelton, W.P., Manley, B., Spiess, P.E.
    • Journal: Frontiers in Oncology
    • Year: 2021
    • Citations: 5 🧬🩺💉